ロード中...
FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
On May 17, 2016, after an expedited priority review, the U.S. Food and Drug Administration granted accelerated approval to nivolumab for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5423515/ https://ncbi.nlm.nih.gov/pubmed/28438889 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0004 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|